Clinical Research Details

Descriptive Information
A Collaborative Pediatric Bone Tumor Program to improve access to specialized care- an initiative by the Lebanese Children’s Oncology Group

Raya Saab


Clinical Research - Outcomes Research and Health Services Research  

  • Miguel R.Abboud
  • Samar Muwakkit
  • Peter Noun
  • Gladys Gemaye
  • Elie Bechara
  • Hassan Khalifeh
  • Roula Farah
  • Nabil Kabbara
  • Tarek El-Khoury
  • Rasha Al-Yousef
  • Rachid Haidar
  • Said Saghieh
  • Toufic Eid
  • Samir Akel
  • Nabil Khoury
  • Layal Bayram
  • Matthew J. Krasin
  • Sima Jeha
  • Hassan El-Solh
Zeina Merabi
Conditions and Keywords
National collaboration for optimal clinical care of prdiatric patients with malignant bone tumors
Bone Tumors,Pediatrics,Global Oncology
Study Design
Health Services Research
N/A: Not Applicable
Eligibility and IRB
Min: 0
Max: 18

 In Lebanon, a small country in the Middle East, there are a total of less than 20 pediatric oncologists, who work at multiple hospitals across the country. In 2012, within a program development initiative sponsored by St Jude Children’s Research Hospital, the majority of pediatric oncologists agreed to establish a cooperative group, within which to initiate collaborative treatment programs for childhood tumors. The hypothesis is that centralized diagnosis and staging and coordinated treatment would result in better patient outcomes. Outcome would also be improved by enhanced access to technically specialized and expensive procedures by eliminating financial barriers, and ensuring expert care.

To establish feasibility, the newly formed group (Lebanese Children’s Oncology Group, LCOG) focused first on pediatric bone tumors. The most common malignant pediatric bone tumors are Osteosarcoma and Ewing sarcoma.


Patients aged below 18 years diagnosed with Ewing’s Sarcoma or Osteosarcoma that were enrolled on the collaborative Bone Tumor and in the period of July 1 2012 to June 30 2015

 Retrospective chart review will be applied to all children diagnosed with Ewing’s Sarcoma and Osteosarcoma that were enrolled on the Collaborative Bone Tumor program between July 1, 2012 and June 30, 2015

Collected data include chemotherapy details, associated delays and toxicities, local control modality (surgery, radiation), acute and chronic complications, and patient outcome  

 1- Patients younger than the age of 18 years of age

2- Diagnosed with Ewing’s or osteosarcoma

3- Enrolled on the collaborative bone tumor program

 Patients who do not fit the inclusion criteria are not eligible.